Showing 2551-2560 of 20412 results for "".
The United Nations Initiative to Reduce Childhood Mortality
https://reachmd.com/programs/clinicians-roundtable/the-united-nations-initiative-to-reduce-childhood-mortality/3872/In 2000 the UN developed the Millennium Developmental Goals and the fourth goal is to reduce child mortality by 2015. Dr. Trevor Duke is head of the Centre for International Child Health in Australia and collaborates with the World Health Organization to meet this goal. He is interviewed by Dr. ShirHow Does Healthcare Policy Impact Physicians?
https://reachmd.com/programs/focus-on-public-health-policy/how-does-healthcare-policy-impact-physicians/3683/Who controls our professional lives? The policymakers do, of course. Join host Dr. Bill Rutenberg and his guest Dr. Aaron Carroll, associate professor of pediatrics and director of the Center for Health Policy and Professionalism Research at the Indiana University School of Medicine as they exploreTreating & Preventing Pediatric Overuse Injuries
https://reachmd.com/programs/clinicians-roundtable/treating-preventing-pediatric-overuse-injuries/3275/More and more children are presenting with overuse injuries. What is happening at the cellular level and how do their bodies repair? Dr. Paul Stricker, board certified in both pediatrics and sports medicine joins host Dr. Bill Rutenberg to discuss pediatric overuse injuries. They discuss the need foImproving Early Detection of Geographic Atrophy
https://reachmd.com/programs/eye-on-ocular-health/improving-early-detection-geographic-atrophy/54793/Geographic atrophy can progress silently before patients notice meaningful vision changes, making early detection critical to preserving long-term retinal health. Fortunately, advances in imaging and emerging biomarkers are helping clinicians identify higher-risk patients earlier and refine monitoriThe Hidden Burden of Infant Eczema: Supporting Patients and Families
https://reachmd.com/programs/dermconsult/infant-eczema-burden-families/60651/Infant eczema can have a profound impact on both patients and their caregivers, even when skin findings appear mild. In this episode, Dr. Mariam Iqneibi discusses the importance of assessing the full burden of disease, validating caregiver concerns, and recognizing how disrupted sleep, feeding challInfectious Disease Care Through the Lens of Patient Context
https://reachmd.com/programs/clinicians-roundtable/infectious-disease-patient-context/48843/How do lived experience, community dynamics, and socioeconomic realities shape infectious disease risk and patient decision making? Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College of Physicians, explains how incorporating patient context into communicaOctane Aesthetics Tech Forum: Clinical Insights Shaping 2026
https://reachmd.com/conferences/octane-atf-2026/octane-aesthetics-tech-forum-clinical-insights-shaping-2026/54712/Patricia Walker, MD, PhD, Founder and President of Walker Consulting, dives into key insights from the Octane Aesthetics Tech Forum and how they may influence the industry in 2026.Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis
https://reachmd.com/programs/frontlines-psoriasis/tyk2-inhibitors-plaque-psoriasis-potential/39952/With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational BiomedGiredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
https://reachmd.com/programs/project-oncology/giredestrant-and-everolimus-in-hrher2-breast-cancer-insights-from-evera/36162/As treatment options evolve for patients with HR+/HER2- advanced breast cancer following CDK 4/6 inhibitor therapy, combination strategies are gaining momentum. The evERA Breast Cancer study, which was presented at the 2025 ESMO Congress, explored one dual-targeted approach—giredestrant and everolimEffector Cell Response Inhibitors
https://reachmd.com/videos/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous ur